The aim of this study was to assess the effect of withdrawal from the long-term use of temazepam, zopiclone or zolpidem as hypnotics drugs (here referred to as BZD) on cognitive performance.
Ninety-two adults (age ≥55 years) with primary insomnia and who were long-term daily users of BZD volunteered to participate in a 1-month medically supported withdrawal attempt from BZD use, with a subsequent 5-month follow-up. Withdrawal was based on plasma BZD measurements at baseline, at 1 month and during subsequent regular clinical appointments. Attention and psychomotor performance were measured using the CogniSpeed® at baseline and at 1, 2 and 6 months. Reaction times were determined in the Simple Reaction Time (SRT), Two-Choice Reaction Time (2-CRT) and Vigilance tests, and errors were measured by the 2-CRT and Vigilance tests. The cognition data of the withdrawal group were also compared with a cohort of BZD non-users.
Eighty-nine (97 %) participants (59 women, 30 men) were followed-up for a maximum of 6 months. During the follow-up period, changes in reaction times and errors did not differ between short-term withdrawers (no residual BZD at 1 month; N = 69), non-withdrawers (residual BZD at 1 month; N = 20) or long-term withdrawers (N = 34). Compared to the reaction times of the BZD-free cohort, those of BZD users were slower at baseline. The reaction times of BZD withdrawers based on the results of the SRT or 2-CRT tests during follow-up did not reach those of the BZD-free cohort, but there was no difference between these groups in the Vigilance test.
Long-term use of BDZ as hypnotic drugs by older adults is related to prolonged impairment of attentional and psychomotor cognitive functioning that persists for at least 6 months after withdrawal.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Barker MJ, Greenwood KM, Crowe SF (2003) Cognitive effects of benzodiazepine use: a review. Aust Psychol 38(3):12
Stewart SA (2005) The effects of benzodiazepines on cognition. J Clin Psychiatry 66[Suppl 2]:9–13
Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE (2005) Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 331(7526):1169
Bierman EJ, Comijs HC, Gundy CM, Sonnenberg C, Jonker C, Beekman AT (2007) The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent? Int J Geriatr Psychiatry 22(12):1194–1200
Hanlon JT, Horner RD, Schmader KE, Fillenbaum GG, Lewis IK, Wall WE Jr, Landerman LR, Pieper CF, Blazer DG, Cohen HJ (1998) Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther 64(6):684–692
Paterniti S, Dufouil C, Alperovitch A (2002) Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol 22(3):285–293
Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y (2012) Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health 66(10):869–873. doi:10.1136/jech-2011-200314
Billioti de Gage S, Bégaud B, Bazin F, Vermeeren A, Dartigues JF, Pèrés K, Kurth T, Pariente A (2012) Benzodiazepine use and risk of dementia: prospective population based study. BMJ 345:e6231. doi:10.1136/bmj.e6231
Puustinen J, Nurminen J, Lopponen M, Vahlberg T, Isoaho R, Raiha I, Kivela SL (2011) Use of CNS medications and cognitive decline in the aged: a longitudinal population-based study. BMC Geriatr 11:70. doi:10.1186/1471-2318-11-70
Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198
Puustinen J, Nurminen J, Vahlberg T, Lyles A, Isoaho R, Raiha I, Kivelä SL (2012) CNS Medications as predictors of precipitous cognitive decline in the cognitively disabled aged: a longitudinal population-based study. Dement Geriatr Cogn Disord Extra 2:57–68. doi:10.1159/000336710
Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004) Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 18(1):37–48
McAndrews MP, Weiss RT, Sandor P, Taylor A, Carlen PL, Shapiro CM (2003) Cognitive effects of long-term benzodiazepine use in older adults. Hum Psychopharmacol 18(1):51–57. doi:10.1002/hup.453
Rummans TA, Davis LJ Jr, Morse RM, Ivnik RJ (1993) Learning and memory impairment in older, detoxified, benzodiazepine-dependent patients. Mayo Clin Proc 68(8):731–737
Curran HV, Collins R, Fletcher S, Kee SC, Woods B, Iliffe S (2003) Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med 33(7):1223–1237
Salzman CF, Nobel K, Glassman R, Wolfson A, Kelley M (1992) Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. Int J Geriatr Psychiatry 7:89–93
Tsunoda K, Uchida H, Suzuki T, Watanabe K, Yamashima T, Kashima H (2010) Effects of discontinuing benzodiazepine-derivative hypnotics on postural sway and cognitive functions in the elderly. Int J Geriatr Psychiatry 25(12):1259–1265. doi:10.1002/gps.2465
Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004) Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol: Off J Natl Acad Neuropsychol 19(3):437–454. doi:10.1016/S0887-6177(03)00096-9
Barker MJ, Greenwood KM, Jackson M, Crowe SF (2005) An evaluation of persisting cognitive effects after withdrawal from long-term benzodiazepine use. J Int Neuropsychol Soc 11(3):281–289. doi:10.1017/S1355617705050332
Lähteenmäki R, Puustinen J, Vahlberg T, Lyles A, Neuvonen PJ, Partinen M, Räihä I, Kivelä S-L (2013) Melatonin for sedative withdrawal in older patients with primary insomnia: a randomised double-blind placebo-controlled trial. Br J Clin Pharmacol. doi:10.1111/bcp.12294
Alhola P, Polo-Kantola P, Erkkola R, Portin R (2006) Estrogen therapy and cognition: a 6-year single-blind follow-up study in postmenopausal women. Neurology 67(4):706–709. doi:10.1212/01.wnl.0000230135.10179.86
Alhola P, Tuomisto H, Saarinen R, Portin R, Kalleinen N, Polo-Kantola P (2010) Estrogen + progestin therapy and cognition: a randomized placebo-controlled double-blind study. J Obstet Gynaecol Res 36(4):796–802. doi:10.1111/j.1447-0756.2010.01214.x
Karakorpi M, Alhola P, Urrila AS, Kylmala M, Portin R, Kalleinen N, Polo-Kantola P (2006) Hormone treatment gives no benefit against cognitive changes caused by acute sleep deprivation in postmenopausal women. Neuropsychopharmacology 31(9):2079–2088. doi:10.1038/sj.npp.1301056
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
Otmani S, Demazieres A, Staner C, Jacob N, Nir T, Zisapel N, Staner L (2008) Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol 23(8):693–705. doi:10.1002/hup.980
Almeida OP, Almeida SA (1999) Short versions of the geriatric depression scale: a study of their validity for the diagnosis of a major depressive episode according to ICD-10 and DSM-IV. Int J Geriatr Psychiatry 14(10):858–865
Kujala P, Portin R, Revonsuo A, Ruutiainen J (1994) Automatic and controlled information processing in multiple sclerosis. Brain 117(Pt 5):1115–1126
Kujala P, Portin R, Revonsuo A, Ruutiainen J (1995) Attention related performance in two cognitively different subgroups of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 59(1):77–82
Revonsuo A, Portin R, Koivikko L, Rinne JO, Rinne UK (1993) Slowing of information processing in Parkinson’s disease. Brain Cognition 21(1):87–110. doi:10.1006/brcg.1993.1007
Lilja AM, Portin RI, Hamalainen PI, Salminen EK (2001) Short-term effects of radiotherapy on attention and memory performances in patients with brain tumors. Cancer 91(12):2361–2368
Ashton H (1991) Protracted withdrawal syndromes from benzodiazepines. J Subst Abuse Treat 8(1–2):19–28
Roy-Byrne PP (2005) The GABA-benzodiazepine receptor complex: structure, function, and role in anxiety. J Clin Psychiatry 66[Suppl 2]:14–20
Lopez-Munoz F, Alamo C, Garcia-Garcia P (2011) The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: half a century of anxiolytic drugs. J Anxiety Disord 25(4):554–562. doi:10.1016/j.janxdis.2011.01.002
Portin R, Polo-Kantola P, Polo O, Koskinen T, Revonsuo A, Irjala K, Erkkola R (1999) Serum estrogen level, attention, memory and other cognitive functions in middle-aged women. Climacteric 2(2):115–123
Portin R, Revonsuo A, Koivikko L, Rinne J (1992) Kognitiivinen hitaus ja vanheneminen [Cognitive slowness and ageing]. Gerontologia [Gerontology] 6(3):196–210
Fortier-Brochu E, Beaulieu-Bonneau S, Ivers H, Morin CM (2012) Insomnia and daytime cognitive performance: a meta-analysis. Sleep Med Rev 16(1):83–94. doi:10.1016/j.smrv.2011.03.008
Chavez EL, Trautt GM, Brandon A, Steyaert J (1983) Effects of test anxiety and sex of subject on neuropsychological test performance: finger tapping, trail making, digit span and digit symbol tests. Percep Motor Skills 56(3):923–929
Gladsjo JA, Rapaport MH, McKinney R, Lucas JA, Rabin A, Oliver T, Davis J, Auerbach M, Judd LL (1998) A neuropsychological study of panic disorder: negative findings. J Affect Disord 49(2):123–131
Acknowledgments, author contributions and competing financial interests
See ESM Acknowledgments.
Electronic supplementary material
Below is the link to the electronic supplementary material.
(DOCX 30.6 kb)
About this article
Cite this article
Puustinen, J., Lähteenmäki, R., Polo-Kantola, P. et al. Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults. Eur J Clin Pharmacol 70, 319–329 (2014). https://doi.org/10.1007/s00228-013-1613-6
- Long-term effects